Altimmune (ALT) Change in Acquisitions & Divestments (2017 - 2026)

Altimmune (ALT) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $39.6 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 4.16% year-over-year to $39.6 million in Q1 2026; TTM through Mar 2026 was $154.6 million, a 38.77% increase from a year earlier, with the FY2025 full-year figure at $153.0 million, up 75.15% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $39.6 million, up from $9.4 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for ALT reached as high as $105.5 million in Q2 2025 and fell as low as $9.4 million in Q4 2025.
• Historically, Change in Acquisitions & Divestments has averaged $31.9 million across 4 years, with a median of $26.4 million in 2023.
• On a YoY basis, Change in Acquisitions & Divestments climbed as much as 441.28% in 2025 and fell as far as 65.0% in 2025.
• Year by year, Change in Acquisitions & Divestments stood at $25.9 million in 2023, then grew by 3.78% to $26.8 million in 2024, then sank by 65.0% to $9.4 million in 2025, then surged by 321.65% to $39.6 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $39.6 million in Q1 2026, $9.4 million in Q4 2025, and $105.5 million in Q2 2025.